Dr. Georgios V. Georgakis, MD, PhD

About Dr. Georgakis

Dr. Georgakis leads the Division of Surgical Oncology at Stony Brook Cancer Center and treats patients with asbestos-related diseases, including peritoneal mesothelioma. His expertise includes cytoreductive surgery combined with HIPEC and pressurized intraperitoneal aerosolized chemotherapy, or PIPAC. 

He is the only doctor in the U.S. using this procedure but is training other surgeons to use it. Dr. Georgakis also uses minimally invasive robotic surgical techniques when possible to improve recovery. He believes in combining cutting-edge surgery and research to offer personalized, effective care for asbestos-related cancers.

Dr. Georgakis’ Medical Education & Expertise

• NKUA Medical School
• Stony Brook Cancer Center
• University of Pittsburgh (Fellowship)
• University of Connecticut Health Center (Residency) 
• Hartford Hospital (Fellowship)
• University of Connecticut Health Center (Residency)
• UMass Medical School (Intern)
• MD Anderson Cancer Center (Fellowship)
• University of Athens (Ph.D.)
• University of Athens (M.D.)

Associations, Awards & Recognition

• Alexander S. Onassis Public Benefit Foundation Research Scholarship (2007-08)
• American Association for Cancer Research
• Americas Hepato-Pancreato-Biliary Association 
• American Society of Clinical Oncology 
• Fellow, American College of Surgeons (FACS)
• Ludwig J. Pyrtek MD Memorial Award, Outstanding Resident in General Surgery, University of Connecticut (2013-14)
• Resident Research Competition Award, University of Connecticut (2013-14)
• Society of Surgical Oncology

Why Choose Dr. Georgakis for Peritoneal Mesothelioma?

Dr. Georgakis has extensive experience treating asbestos-related peritoneal mesothelioma, combining surgery and advanced chemotherapy techniques to improve outcomes. His approach uses a blend of robotic, laparoscopic and open surgery, tailoring treatment for each person’s unique needs. His ongoing research in regional perfusion therapies ensures patients have access to the latest, evidence-based treatments.

Publications of Dr. Georgakis

• Georgakis, GV et al. (2008, August 15). Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Retrieved from https://pubmed.ncbi.nlm.nih.gov/18541724/
• Georgakis, GV et al. (2005, October 18). Expression of heat-shock protein-90 in non-Hodgkin’s lymphomas. Retrieved from https://pubmed.ncbi.nlm.nih.gov/16056252/
• Georgakis, GV et al. (2004, August 17). Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Retrieved from https://pubmed.ncbi.nlm.nih.gov/15105813/
• Georgakis, GV et al. (2004, May). Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Retrieved from https://pubmed.nci.nlm.nih.gov/15131062/
• Georgakis, GV et al. (2003, December 15). c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. Retrieved from https://pubmed.ncbi.nlm.nih.gov/14656871/